Disclosures for "RACK1 Knockdown is a Potential Therapeutic Target in ALS and FTLD-TDP")
-
Dr. Cashman has received personal compensation for serving as an employee of ProMIS Neurosciences. Dr. Cashman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi-Tanabe. Dr. Cashman has stock in ProMIS Neurosciences. The institution of Dr. Cashman has received research support from ProMIS Neurosciences. Dr. Cashman has received intellectual property interests from a discovery or technology relating to health care. Dr. Cashman has a non-compensated relationship as a BoD memeber with ALS Society of BC that is relevant to AAN interests or activities.
-
Beibei Zhao has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Cowan has nothing to disclose.
-
Miss Saraph has nothing to disclose.
-
Mr. Christy has nothing to disclose.
-
Ms. Coutts has nothing to disclose.
-
Dr. Kaplan has received personal compensation for serving as an employee of ProMIS Neurosciences. Dr. Kaplan has received stock or an ownership interest from ProMIS Neurosciences. Dr. Kaplan has received intellectual property interests from a discovery or technology relating to health care.